Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 10Active not recruiting 3Terminated 2Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 15Carcinoma, Hepatocellular 13Urinary Bladder Neoplasms 12Colorectal Neoplasms 11Small Cell Lung Carcinoma 9Neoplasms 8Carcinoma, Transitional Cell 8Stomach Neoplasms 7Neoplasm Metastasis 7Breast Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Ovarian Neoplasms 3Carcinoma, Neuroendocrine 3Urethral Neoplasms 2Ureteral Neoplasms 2Turcot syndrome 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Rectal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Glioma 2

Interventions

pembrolizumab 10Cisplatin 7Radiotherapy 6Magnetic Resonance Spectroscopy 6Carboplatin 6Specimen Handling 5Paclitaxel 5Brachytherapy 5Fluorodeoxyglucose F18 4dostarlimab 3atezolizumab 3Trastuzumab 3Radiation 3Platinum 3Nivolumab 3Human Papillomavirus DNA Tests 3Docetaxel 3Colposcopy 31,2-diaminocyclohexaneplatinum II citrate 3zimberelimab 2tislelizumab 2spartalizumab 2olaparib 2human papillomavirus vaccine, L1 type 16, 18 2durvalumab 2Vaccines 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiation Dose Hypofractionation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Uterine Cervical Neoplasms × atezolizumab × Clear all
NCT03614949 2026-04-01

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
21 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03340376 2024-07-03

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Universitaire Ziekenhuizen KU Leuven

Phase 2 Active not recruiting
48 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡